{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:15:24Z","timestamp":1760904924902,"version":"build-2065373602"},"reference-count":252,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.critrevonc.2022.103592","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:56:04Z","timestamp":1641815764000},"page":"103592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies"],"prefix":"10.1016","volume":"170","author":[{"given":"Hanno M.","family":"Witte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0566-4554","authenticated-orcid":false,"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Steinestel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.critrevonc.2022.103592_bib0005","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0010","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.7150\/thno.42986","article-title":"The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities","volume":"10","author":"Alame","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm?","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103592_bib0020","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000186","article-title":"On the mechanism of anti-CD39 immune checkpoint therapy","volume":"8","author":"Allard","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12307-015-0174-x","article-title":"Characterization of M1\/M2 tumour-associated macrophages (TAMs) and Th1\/Th2 cytokine profiles in patients with NSCLC","volume":"9","author":"Almatroodi","year":"2016","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.oooo.2019.06.578","article-title":"A systematic review of secretory carcinoma of the salivary gland: where are we?","author":"Alves","year":"2020","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103592_bib0050","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1002\/cncr.25852","article-title":"A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)","volume":"117","author":"Argiris","year":"2011","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092466","article-title":"Expression profiling of extracellular matrix genes reveals global and entity-specific characteristics in adenoid cystic, mucoepidermoid and salivary duct carcinomas","volume":"12","author":"Arolt","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0060","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00262-020-02551-6","article-title":"Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas","volume":"69","author":"Arolt","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.01.013","article-title":"Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone?","volume":"343","author":"Badalamenti","year":"2019","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171265","article-title":"Recurrent rearrangements of the Myb\/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma","volume":"12","author":"Barasch","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0075","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","article-title":"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","article-title":"Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland","volume":"476","author":"Bell","year":"2020","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2010.10.013","article-title":"Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer","volume":"47","author":"Bello","year":"2011","journal-title":"Oral Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0090","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12105-020-01128-0","article-title":"Low-grade apocrine intraductal carcinoma: expanding the morphologic and molecular spectrum of an enigmatic salivary gland tumor","volume":"14","author":"Bishop","year":"2020","journal-title":"Head Neck Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/his.14296","article-title":"Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations","volume":"79","author":"Bishop","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.oraloncology.2018.04.022","article-title":"Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands","volume":"82","author":"Boon","year":"2018","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0105","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/modpathol.2011.86","article-title":"Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms","volume":"24","author":"Brill","year":"2011","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.18632\/oncotarget.13477","article-title":"Inhibition of the transcriptional repressor complex Bcl-6\/BCoR induces endothelial sprouting but does not promote tumor growth","volume":"8","author":"Buchberger","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0115","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2407-9-391","article-title":"Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior","volume":"9","author":"Cardoso","year":"2009","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<207::AID-CNCR4>3.0.CO;2-Q","article-title":"Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases","volume":"86","author":"Castle","year":"1999","journal-title":"Cancer"},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2022.103592_bib0130","doi-asserted-by":"crossref","first-page":"vii83","DOI":"10.1093\/annonc\/mds266","article-title":"Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Chan","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0135","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2147\/OTT.S134589","article-title":"Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors","volume":"10","author":"Chang","year":"2017","journal-title":"Onco. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0140","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s12105-020-01163-x","article-title":"Increased ERBB2 gene copy numbers reveal a subset of salivary duct carcinomas with high densities of tumor infiltrating lymphocytes and PD-L1 expression","volume":"14","author":"Chatzopoulos","year":"2020","journal-title":"Head Neck Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0145","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.25011\/cim.v44i1.35218","article-title":"Assessment of tumour infiltrating lymphocytes and Pd-l1 expression in adenoid cystic carcinoma of the salivary gland","volume":"44","author":"Chen","year":"2021","journal-title":"Clin. Invest. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139497","article-title":"The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0155","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0000000000000410","article-title":"Molecular characterization of apocrine salivary duct carcinoma","volume":"39","author":"Chiosea","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0160","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001252","article-title":"Mucoepidermoid carcinoma: a comparison of histologic grading systems and relationship to MAML2 rearrangement and prognosis","volume":"43","author":"Cipriani","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0165","unstructured":"ClinicalTrials.gov. NIH U.S. National Library of Medicine."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.oraloncology.2015.04.005","article-title":"Adenoid cystic carcinoma of the head and neck\u2013an update","volume":"51","author":"Coca-Pelaz","year":"2015","journal-title":"Oral Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0175","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2013-04-496216","article-title":"TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses","volume":"122","author":"Cohen","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0180","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1501139","article-title":"IFN-gamma prevents adenosine receptor (A2bR) upregulation to sustain the macrophage activation response","volume":"195","author":"Cohen","year":"2015","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0185","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0190","first-page":"479","article-title":"NCCN guidelines insights: head and neck cancers, version 1.2018","volume":"16","author":"Colevas","year":"2018","journal-title":"J. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S1010-5182(05)80067-8","article-title":"Acinic cell carcinoma of the salivary glands. A review of 20 new cases","volume":"19","author":"Colmenero","year":"1991","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104615","article-title":"Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression","volume":"103","author":"Cordesmeyer","year":"2020","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0205","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0210","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1200\/JCO.2017.35.15_suppl.6036","article-title":"A phase 1b\/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma","volume":"35","author":"Cote","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0215","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/1097-0142(19831201)52:11<2007::AID-CNCR2820521106>3.0.CO;2-T","article-title":"Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer","volume":"52","author":"Creagan","year":"1983","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0220","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4","article-title":"Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck","volume":"62","author":"Creagan","year":"1988","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103592_bib0225","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0230","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41467-017-01178-z","article-title":"Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions","volume":"8","author":"Dalin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.critrevonc.2016.03.018","article-title":"Clear cell carcinoma, not otherwise specified\/hyalinising clear cell carcinoma of the salivary gland: the current nomenclature, clinical\/pathological characteristics and management","volume":"102","author":"Daniele","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0240","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.joms.2015.10.014","article-title":"Neutron beam radiation therapy: an overview of treatment and oral complications when treating salivary gland malignancies","volume":"74","author":"Davis","year":"2016","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0245","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/odi.12984","article-title":"T(6;9)(MYB-NFIB) in head and neck adenoid cystic carcinoma: a systematic review with meta-analysis","volume":"25","author":"de Almeida-Pinto","year":"2019","journal-title":"Oral Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0250","first-page":"1","article-title":"Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer","volume":"7","author":"Debaere","year":"2011","journal-title":"B-ENT"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0255","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.oooo.2011.11.019","article-title":"Salivary adenocarcinoma, not otherwise specified: a clinicopathological study of 28 cases","volume":"113","author":"Deng","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0260","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0265","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molimm.2019.06.006","article-title":"TLR1\/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage","volume":"112","author":"Deng","year":"2019","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0270","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/hed.23925","article-title":"Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials","volume":"38","author":"Dillon","year":"2016","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0275","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0280","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00106-019-00761-8","article-title":"Immunotherapy for head and neck cancer: highlights of the 2019 ASCO annual meeting","volume":"67","author":"Doescher","year":"2019","journal-title":"HNO"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0285","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00106-019-00760-9","article-title":"Salivary gland malignancies-highlights of the 2019 ASCO annual meeting","volume":"67","author":"Doescher","year":"2019","journal-title":"HNO"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0295","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1097-0347(199905)21:3<255::AID-HED11>3.0.CO;2-2","article-title":"Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors","volume":"21","author":"Douglas","year":"1999","journal-title":"Head Neck"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0300","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0305","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0310","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2018.36.15_suppl.2515","article-title":"A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors","volume":"36","author":"El-Khoueiry","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7261","key":"10.1016\/j.critrevonc.2022.103592_bib0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2017.05.014","article-title":"The fourth edition of the head and neck World Health Organization blue book: editors\u2019 perspectives","volume":"66","author":"El-Naggar","year":"2017","journal-title":"Hum. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0325","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1600-0714.2010.00879.x","article-title":"Association of macrophages with angiogenesis in oral verrucous and squamous cell carcinomas","volume":"39","author":"El-Rouby","year":"2010","journal-title":"J. Oral Pathol. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0330","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0335","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrc2460","article-title":"A new MAFia in cancer","volume":"8","author":"Eychene","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103592_bib0340","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0345","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/rccm.201204-0636OC","article-title":"CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer","volume":"186","author":"Feng","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0350","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10753-013-9621-3","article-title":"The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling","volume":"36","author":"Ferrante","year":"2013","journal-title":"Inflammation"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0355","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0360","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.imlet.2018.03.007","article-title":"Canonical and non-canonical adenosinergic pathways","volume":"205","author":"Ferretti","year":"2019","journal-title":"Immunol. Lett."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0370","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/00000478-199612000-00002","article-title":"Salivary gland cystadenocarcinomas. A clinicopathologic study of 57 cases","volume":"20","author":"Foss","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150084","article-title":"Poxvirus-based active immunotherapy with PD-1 and LAG-3 dual immune checkpoint inhibition overcomes compensatory immune regulation, yielding complete tumor regression in mice","volume":"11","author":"Foy","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0385","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ijom.2013.04.006","article-title":"Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma","volume":"42","author":"Gao","year":"2013","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0390","first-page":"79","article-title":"Phase (Ph) I\/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies","author":"Giuseppe Curigliano","year":"2019","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0395","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/PAS.0b013e31805f6775","article-title":"Myoepithelial carcinoma of soft tissue in children: an aggressive neoplasm analyzed in a series of 29 cases","volume":"31","author":"Gleason","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0400","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41467-017-00985-8","article-title":"Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane","volume":"8","author":"Glentis","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0405","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12105-012-0343-x","article-title":"My journey into the world of salivary gland sebaceous neoplasms","volume":"6","author":"Gnepp","year":"2012","journal-title":"Head Neck Pathol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103592_bib0410","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0420","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/PAS.0b013e3182880d5a","article-title":"PIK3CA mutations and PTEN loss in salivary duct carcinomas","volume":"37","author":"Griffith","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0425","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/his.12454","article-title":"Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma","volume":"65","author":"Griffith","year":"2014","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0430","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0435","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0440","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-018-08069-x","article-title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands","volume":"10","author":"Haller","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0445","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/PAS.0000000000001279","article-title":"Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands","volume":"43","author":"Haller","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0450","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.oraloncology.2017.02.005","article-title":"Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck","volume":"67","author":"Hanna","year":"2017","journal-title":"Oral Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0455","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-Positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103592_bib0460","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0465","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12885-018-4069-3","article-title":"PD-L1 expression in malignant salivary gland tumors","volume":"18","author":"Harada","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0470","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","article-title":"Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity","volume":"60","author":"Hausler","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"7520","key":"10.1016\/j.critrevonc.2022.103592_bib0475","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13688","article-title":"Inhibition of demethylases by GSK-J1\/J4","volume":"514","author":"Heinemann","year":"2014","journal-title":"Nature"},{"issue":"237","key":"10.1016\/j.critrevonc.2022.103592_bib0480","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103592_bib0485","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0490","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050965","article-title":"Tumour-infiltrating lymphocytes (TILs) and PD-L1 expression correlate with lymph node metastasis, high-grade transformation and shorter metastasis-free survival in patients with acinic cell carcinoma (AciCC) of the salivary glands","volume":"13","author":"Hiss","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0495","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Ho","year":"2013","journal-title":"Nat. Genet."},{"issue":"15 Suppl","key":"10.1016\/j.critrevonc.2022.103592_bib0500","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1200\/JCO.2019.37.15_suppl.6020","article-title":"Alliance A091404: a phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers","volume":"37","author":"Ho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0505","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","author":"Ho","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0515","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0520","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/00000478-200309000-00001","article-title":"Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters","volume":"27","author":"Hornick","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0525","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-020-02823-7","article-title":"Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type","volume":"477","author":"Hsieh","year":"2020","journal-title":"Virchows Arch."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0530","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0535","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/his.13845","article-title":"Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma","volume":"75","author":"Hung","year":"2019","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0540","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI0215518","article-title":"Evidence that fibroblasts derive from epithelium during tissue fibrosis","volume":"110","author":"Iwano","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0545","first-page":"3045","article-title":"Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck","volume":"37","author":"Jang","year":"2017","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0550","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hed.23350","article-title":"Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database","volume":"36","author":"Jayaprakash","year":"2014","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0555","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/modpathol.2012.154","article-title":"Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma","volume":"26","author":"Jee","year":"2013","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0560","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1078-0432.CCR-16-0720","article-title":"Whole-exome sequencing of salivary gland mucoepidermoid carcinoma","volume":"23","author":"Kang","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0565","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12105-017-0796-z","article-title":"Update from the 4th Edition of the World Health Organization classification of head and neck tumours: what is new in the 2017 WHO blue book for tumors and tumor-like lesions of the neck and lymph nodes","volume":"11","author":"Katabi","year":"2017","journal-title":"Head Neck Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0570","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.humpath.2009.12.011","article-title":"Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases","volume":"41","author":"Katabi","year":"2010","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0575","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/his.12488","article-title":"Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading","volume":"65","author":"Katabi","year":"2014","journal-title":"Histopathology"},{"issue":"32","key":"10.1016\/j.critrevonc.2022.103592_bib0580","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0585","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0590","doi-asserted-by":"crossref","first-page":"14995","DOI":"10.1038\/s41598-020-72096-2","article-title":"Integrative genomic analysis of salivary duct carcinoma","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103592_bib0595","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/0008-5472.CAN-13-0602","article-title":"Integrin alphavbeta3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis","volume":"73","author":"Knowles","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15419061.2018.1464000","article-title":"Establishment and characterization of a carcinoma-associated fibroblast cell line derived from a human salivary gland adenoid cystic carcinoma","volume":"24","author":"Kong","year":"2018","journal-title":"Cell Commun. Adhes."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0605","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.31557\/APJCP.2019.20.12.3547","article-title":"Angiogenesis and Lymphangiogenesis in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma","volume":"20","author":"Koochek Dezfuli","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"132","key":"10.1016\/j.critrevonc.2022.103592_bib0610","doi-asserted-by":"crossref","first-page":"ra55","DOI":"10.1126\/scisignal.2000588","article-title":"Autocrine purinergic receptor signaling is essential for macrophage chemotaxis","volume":"3","author":"Kronlage","year":"2010","journal-title":"Sci. Signal."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2022.103592_bib0615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0924-4212(96)84897-3","article-title":"European results in neutron therapy of malignant salivary gland tumors","volume":"83","author":"Krull","year":"1996","journal-title":"Bull. Cancer Radiother."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0620","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0625","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","article-title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","volume":"139","author":"Levental","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0630","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/hupa.2001.25000","article-title":"Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases","volume":"32","author":"Lewis","year":"2001","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0635","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s12032-014-0957-9","article-title":"A clinical analysis of 37 cases with lymphoepithelial carcinoma of the major salivary gland treated by surgical resection and postoperative radiotherapy: a single institution study","volume":"31","author":"Li","year":"2014","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0640","article-title":"Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0645","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1320011","article-title":"CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer","volume":"6","author":"Li","year":"2017","journal-title":"Oncoimmunology"},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103592_bib0650","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015402","article-title":"Expression of MIF, Beclin1, and LC3 in human salivary gland adenoid cystic carcinoma and its prognostic value","volume":"98","author":"Li","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.12.003","article-title":"Cancer-associated fibroblasts in tumor microenvironment - accomplices in tumor malignancy","volume":"343","author":"Liao","year":"2019","journal-title":"Cell. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0660","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0665","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0670","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11899-019-00523-x","article-title":"Tumor-infiltrating lymphocytes in the checkpoint inhibitor era","volume":"14","author":"Linette","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0675","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0680","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","article-title":"The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype","volume":"26","author":"Linxweiler","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0685","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-012-1330-z","article-title":"Overexpression of macrophage migration inhibitory factor in adenoid cystic carcinoma: correlation with enhanced metastatic potential","volume":"139","author":"Liu","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0690","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hed.25597","article-title":"The value of MYB as a prognostic marker for adenoid cystic carcinoma: meta-analysis","volume":"41","author":"Liu","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0695","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jop.12784","article-title":"JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways","volume":"48","author":"Liu","year":"2019","journal-title":"J. Oral Pathol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0700","first-page":"1085","article-title":"Potential targets identified in adenoid cystic carcinoma point out new directions for further research","volume":"13","author":"Liu","year":"2021","journal-title":"Am. J. Transl. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib0705","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0710","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-417028-5.00006-5","article-title":"Macrophage activation and polarization as an adaptive component of innate immunity","volume":"120","author":"Locati","year":"2013","journal-title":"Adv. Immunol."},{"issue":"27","key":"10.1016\/j.critrevonc.2022.103592_bib0715","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0720","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/omi.2013.0058","article-title":"SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention","volume":"17","author":"Lou","year":"2013","journal-title":"OMICS"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2022.103592_bib0725","first-page":"E1838","article-title":"Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations","volume":"38","author":"Luk","year":"2016","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0730","first-page":"507","article-title":"AGR2 promotes the proliferation, migration and regulates epithelial-mesenchymal transition in salivary adenoid cystic carcinoma","volume":"9","author":"Ma","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0735","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Macon-Lemaitre","year":"2005","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0740","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/path.4133","article-title":"Macrophage plasticity and polarization in tissue repair and remodelling","volume":"229","author":"Mantovani","year":"2013","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0745","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0750","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijom.2010.12.002","article-title":"Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas","volume":"40","author":"Mariano","year":"2011","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0755","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2019.04.014","article-title":"Prognostic importance of the lymphovascular invasion in head and neck adenoid cystic carcinoma: a systematic review and meta-analysis","volume":"93","author":"Martins-Andrade","year":"2019","journal-title":"Oral Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2022.103592_bib0760","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/cncr.26697","article-title":"Prognostic factors in mucoepidermoid carcinoma of the salivary glands","volume":"118","author":"McHugh","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0765","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0770","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00106-020-00926-w","article-title":"Tumor microenvironment in salivary gland carcinomas: consequences for new therapeutic concepts","volume":"68","author":"Meyer","year":"2020","journal-title":"HNO"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0775","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2019.06.002","article-title":"Polymorphous adenocarcinoma of salivary glands","volume":"95","author":"Mimica","year":"2019","journal-title":"Oral Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0780","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1078-0432.CCR-15-2867-T","article-title":"Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations","volume":"22","author":"Mitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0785","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.11.028","article-title":"Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands","volume":"88","author":"Mosconi","year":"2019","journal-title":"Oral Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0790","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","article-title":"Molecular patterns in salivary duct carcinoma identify prognostic subgroups","volume":"33","author":"Mueller","year":"2020","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0795","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/(SICI)1097-0142(19961215)78:12<2471::AID-CNCR4>3.0.CO;2-N","article-title":"Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature","volume":"78","author":"Muller","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0800","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/his.12086","article-title":"The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases","volume":"62","author":"Muller","year":"2013","journal-title":"Histopathology"},{"year":"2016","series-title":"Janeway\u2019s Immunobiology","author":"Murphy","key":"10.1016\/j.critrevonc.2022.103592_bib0805"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0810","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0815","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41379-019-0427-1","article-title":"Characterization of novel genetic alterations in salivary gland secretory carcinoma","volume":"33","author":"Na","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0820","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.oraloncology.2019.01.015","article-title":"Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas","volume":"90","author":"Nakano","year":"2019","journal-title":"Oral Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib0825","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/modpathol.2009.126","article-title":"Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma","volume":"22","author":"Nakayama","year":"2009","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib0830","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0835","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-16-1235","article-title":"Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas","volume":"23","author":"Nor","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"35","key":"10.1016\/j.critrevonc.2022.103592_bib0840","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0845","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.oraloncology.2016.06.019","article-title":"Salivary Gland. Photon beam and particle radiotherapy: present and future","volume":"60","author":"Orlandi","year":"2016","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0850","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/lary.24231","article-title":"Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases","volume":"124","author":"Patel","year":"2014","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0855","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tranon.2019.11.008","article-title":"Immune response against head and neck cancer: biological mechanisms and implication on therapy","volume":"13","author":"Perri","year":"2020","journal-title":"Transl. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib0860","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0865","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/gcc.20619","article-title":"High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2","volume":"48","author":"Persson","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"44","key":"10.1016\/j.critrevonc.2022.103592_bib0870","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","article-title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck","volume":"106","author":"Persson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0875","doi-asserted-by":"crossref","first-page":"e6040","DOI":"10.1371\/journal.pone.0006040","article-title":"Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2","volume":"4","author":"Phuchareon","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0880","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archotol.130.2.174","article-title":"Prognostic factors in head and neck mucoepidermoid carcinoma","volume":"130","author":"Pires","year":"2004","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0885","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01366959","article-title":"Mucoepidermoid carcinoma of the salivary glands, Clinical data and follow-up of 52 cases","volume":"122","author":"Plambeck","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0890","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clml.2011.06.005","article-title":"CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia","volume":"11","author":"Pulte","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0895","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0900","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2015.10.040","article-title":"Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy","volume":"371","author":"Ramachandran","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0905","first-page":"e213","article-title":"CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors","volume":"11","author":"Ranjbar","year":"2019","journal-title":"J. Clin. Exp. Dent."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103592_bib0910","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1002\/lary.25356","article-title":"MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma","volume":"125","author":"Rettig","year":"2015","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0915","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","article-title":"Whole-genome sequencing of salivary gland adenoid cystic carcinoma","volume":"9","author":"Rettig","year":"2016","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0920","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/intimm\/dxs110","article-title":"Hypoxia-mediated regulation of macrophage functions in pathophysiology","volume":"25","author":"Riboldi","year":"2013","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0925","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0930","article-title":"The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary immunohistochemical profiling and diagnostic criteria","author":"Rooper","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0935","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12105-020-01198-0","article-title":"Salivary intraductal carcinoma arising within intraparotid lymph node: a report of 4 cases with identification of a novel STRN-ALK fusion","volume":"15","author":"Rooper","year":"2021","journal-title":"Head Neck Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib0940","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib0945","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4281","article-title":"Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis","volume":"231","author":"Sandoval","year":"2013","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0950","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"Predictive value of PD-L1 diagnostics","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Pathologe"},{"key":"10.1016\/j.critrevonc.2022.103592_bib0955","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0960","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.pas.0000213314.74423.d8","article-title":"Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract","volume":"31","author":"Seethala","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"1107","key":"10.1016\/j.critrevonc.2022.103592_bib0965","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190516","article-title":"Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies","volume":"93","author":"Seidensaal","year":"2020","journal-title":"Br. J. Radiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib0970","first-page":"95","article-title":"Classification and differential diagnosis of clear and basal cell tumors of the salivary glands","volume":"13","author":"Seifert","year":"1996","journal-title":"Semin. Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib0975","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijom.2012.10.004","article-title":"Small cell carcinoma of the salivary gland: a systematic literature review and two case reports","volume":"42","author":"Servato","year":"2013","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.critrevonc.2022.103592_bib0980","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2020.02.001","article-title":"Pathologic grading of mucoepidermoid carcinomas of the salivary gland and its effect on clinicopathologic follow-up: an institutional experience","volume":"98","author":"Shafique","year":"2020","journal-title":"Hum. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib0985","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/0003489419853597","article-title":"Salivary clear cell carcinoma clinicopathologic characteristics and outcomes: a population-based analysis","volume":"128","author":"Sharbel","year":"2019","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib0990","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1245\/s10434-008-0259-6","article-title":"Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands","volume":"16","author":"Shieh","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib0995","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jop.12155","article-title":"Comparison of adenoid cystic carcinomas arising from the parotid gland vs. the submandibular gland: focus on systemic metastasis and tumor-associated blood vessels","volume":"43","author":"Shin","year":"2014","journal-title":"J. Oral Pathol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1000","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1365-2559.2002.01439.x","article-title":"Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma","volume":"41","author":"Simpson","year":"2002","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib1010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.crad.2015.01.013","article-title":"Patterns of spread of head and neck adenoid cystic carcinoma","volume":"70","author":"Singh","year":"2015","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib1015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdz244","article-title":"Meteor-1: a phase I study of GSK3326595, a first-in-class proteins arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumors","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib1020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Skalova","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0000000000000972","article-title":"Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases","volume":"42","author":"Skalova","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib1030","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/PAS.0000000000001133","article-title":"Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: a report of 17 cases","volume":"42","author":"Skalova","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib1035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/PAS.0000000000001301","article-title":"NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is \u201cintraductal\u201d correct?","volume":"43","author":"Skalova","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib1040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0000000000001535","article-title":"Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion","volume":"44","author":"Skalova","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103592_bib1045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113380","article-title":"Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling","volume":"12","author":"Solimando","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib1050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","article-title":"Salivary gland tumours","volume":"8","author":"Speight","year":"2002","journal-title":"Oral Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0002-9610(74)90265-7","article-title":"Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases","volume":"128","author":"Spiro","year":"1974","journal-title":"Am. J. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0002-9610(82)90416-0","article-title":"Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients","volume":"144","author":"Spiro","year":"1982","journal-title":"Am. J. Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103592_bib1065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib1070","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1172\/JCI67201","article-title":"Whole exome sequencing of adenoid cystic carcinoma","volume":"123","author":"Stephens","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib1080","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1085","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-2007-1013795","article-title":"Pulmonary metastasis of polymorphous low-grade adenocarcinoma of the minor salivary gland","volume":"43","author":"Tanaka","year":"1995","journal-title":"Thorac. Cardiovasc. Surg."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103592_bib1090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"7649","key":"10.1016\/j.critrevonc.2022.103592_bib1095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib1100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/gcc.20458","article-title":"CRTC1\/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin\u2019s tumors: implications for histogenesis and biologic behavior","volume":"46","author":"Tirado","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib1105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.path.2020.09.003","article-title":"Intraductal carcinomas of the salivary gland","volume":"14","author":"Todorovic","year":"2021","journal-title":"Surg. Pathol. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib1110","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41379-018-0008-8","article-title":"MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts","volume":"31","author":"Togashi","year":"2018","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ng1083","article-title":"T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway","volume":"33","author":"Tonon","year":"2003","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0194599815594788","article-title":"Epithelial-myoepithelial carcinoma of the salivary glands: an analysis of 246 cases","volume":"153","author":"Vazquez","year":"2015","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib1125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/JCO.1987.5.6.951","article-title":"Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group","volume":"5","author":"Venook","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103592_bib1130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib1135","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","article-title":"The expression of PD-L1 in salivary gland carcinomas","volume":"9","author":"Vital","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib1140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1368-8375(02)00007-6","article-title":"Carcinoma of the parotid and submandibular glands\u2013a study of survival in 2465 patients","volume":"38","author":"Wahlberg","year":"2002","journal-title":"Oral Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1145","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/annonc\/mdw689","article-title":"Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations","volume":"28","author":"Wang","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1150","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.18632\/oncotarget.13952","article-title":"Management of salivary gland carcinomas - a review","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103592_bib1155","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fonc.2019.01084","article-title":"Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103592_bib1160","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jcms.2014.01.035","article-title":"Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages\u2013an immunohistochemical analysis","volume":"42","author":"Weber","year":"2014","journal-title":"J. Craniomaxillofac. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2559.2011.03937.x","article-title":"Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases","volume":"59","author":"Weiler","year":"2011","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000952","article-title":"Recurrent RET gene rearrangements in intraductal carcinomas of salivary gland","volume":"42","author":"Weinreb","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103592_bib1175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAS.0b013e3182002777","article-title":"MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation","volume":"35","author":"West","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103592_bib1180","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12105-014-0562-4","article-title":"Basal cell adenocarcinoma and Basal cell adenoma of the salivary glands: a clinicopathological review of seventy tumors with comparison of morphologic features and growth control indices","volume":"9","author":"Wilson","year":"2015","journal-title":"Head Neck Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040873","article-title":"Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate","volume":"12","author":"Witte","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1195","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103592_bib1200","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103592_bib1205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103592_bib1210","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0194599816637605","article-title":"Prognostic factors in myoepithelial carcinoma of the major salivary glands","volume":"154","author":"Xiao","year":"2016","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103592_bib1215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"Xu","year":"2019","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13981","article-title":"Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2022.103592_bib1225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.humpath.2020.11.017","article-title":"Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma","volume":"109","author":"Yamamoto","year":"2021","journal-title":"Hum. Pathol."},{"issue":"49","key":"10.1016\/j.critrevonc.2022.103592_bib1230","doi-asserted-by":"crossref","first-page":"84841","DOI":"10.18632\/oncotarget.11002","article-title":"Distribution of lymph node metastasis from lymphoepithelial-like carcinoma of the parotid","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103592_bib1235","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103592_bib1240","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1158\/0008-5472.CAN-17-0393","article-title":"Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis","volume":"77","author":"Young","year":"2017","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103592_bib1245","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103592_bib1250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2020.01.039","article-title":"Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells","volume":"479","author":"Yusenko","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103592_bib1255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cam4.1293","article-title":"AKT3 drives adenoid cystic carcinoma development in salivary glands","volume":"7","author":"Zboray","year":"2018","journal-title":"Cancer Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103592_bib1260","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.7150\/thno.47081","article-title":"Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:41:30Z","timestamp":1760902890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":252,"alternative-id":["S1040842822000166"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103592","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103592"}}